- Home
- CRBP
as 11-21-2024 11:32am EST
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NORWOOD |
| Market Cap: | 227.3M | IPO Year: | N/A |
| Target Price: | $65.86 | AVG Volume (30 days): | 341.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.00 - $61.90 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Corbus Pharmaceuticals Holdings Inc. (CRBP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | CRBP | 10% Owner | Sep 20 '24 | Buy | $19.93 | 350,000 | $7,003,760.61 | 2,070,085 |
Latest Corbus Pharmaceuticals Holdings Inc. News
CRBP Breaking Stock News: Dive into CRBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 hours ago
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
GlobeNewswire
9 days ago
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Simply Wall St.
12 days ago
We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
Associated Press Finance
14 days ago
Corbus Pharmaceuticals: Q3 Earnings Snapshot
GlobeNewswire
14 days ago
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
Investor's Business Daily
17 days ago
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat
GlobeNewswire
17 days ago
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
GlobeNewswire
23 days ago
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
Compare CRBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRBP Corbus Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.